(Q34968951)

5 August 2017

0 references

Economics of Malignant Gliomas: A Critical Review (English)

1 reference

5 August 2017

Jeffrey J Raizer

1

1 reference

5 August 2017

Karen A Fitzner

2

1 reference

5 August 2017

Daniel I Jacobs

3

1 reference

5 August 2017

Charles L Bennett

4

1 reference

5 August 2017

Dustin B Liebling

5

1 reference

5 August 2017

Thanh Ha Luu

6

1 reference

5 August 2017

Steven M Trifilio

7

1 reference

5 August 2017

Sean A Grimm

8

1 reference

5 August 2017

Matthew J Fisher

9

1 reference

5 August 2017

Meraaj S Haleem

10

1 reference

5 August 2017

Paul S Ray

11

1 reference

5 August 2017

Judith M McKoy

12

1 reference

5 August 2017

Rebecca DeBoer

13

1 reference

5 August 2017

Katrina-Marie E Tulas

14

1 reference

5 August 2017

Mohammed Deeb

15

1 reference

5 August 2017

June M McKoy

16

1 reference

5 August 2017

language of work or name

English

0 references

publication date

2 December 2014

1 reference

Journal of Oncology Practice

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

e59-65

1 reference

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Glioblastoma multiforme: a review of where we have been and where we are going

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

The economics of temozolomide in brain cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Cost-of-illness studies : a review of current methods.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

MGMT gene silencing and benefit from temozolomide in glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Alternative valuations of work loss and productivity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Brain tumours in Sweden 1996: care and costs

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Stereotaxy reduces cost of brain tumor resection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

The distinction between cost and charges

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Utilization and cost of health care services associated with primary malignant brain tumors in the United States

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

A cost-minimising analysis of standard radiotherapy and two experimental therapies in glioblastoma.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Treatment costs for glioblastoma multiforme in Nova Scotia.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

The costs of managing patients with malignant glioma at a neuro-oncology clinic.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

High-grade astrocytomas: resource use, clinical outcomes, and cost of care.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4295423

Chemotherapy for malignant gliomas

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25466707

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Utilities and quality-adjusted life years

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25466707

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JOP.2012.000560

1 reference

5 August 2017

1 reference

5 August 2017

1 reference